

(51) International Patent Classification:
A01N 1/02 (2006.01)(21) International Application Number:
PCT/US2021/014114(22) International Filing Date:
20 January 2021 (20.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/964,074 21 January 2020 (21.01.2020) US(71) Applicant: MILLENNIUM PHARMACEUTICALS,
INC. [US/US]; 40 Landsdowne Street, Cambridge, MA
02139 (US).(72) Inventors: CAO, Lan; c/o Millennium Pharmaceuticals,
Inc., 40 Landsdowne Street, Cambridge, MA 02139 (US).

CHANG, Hui-Hsin; c/o Millennium Pharmaceuticals, Inc.,
40 Landsdowne Street, Cambridge, MA 02139 (US). **HU,**
Jianxin; c/o Millennium Pharmaceuticals, Inc., 40 Lands-
downe Street, Cambridge, MA 02139 (US). **SHI, Xi**; c/o
Millennium Pharmaceuticals, Inc., 40 Landsdowne Street,
Cambridge, MA 02139 (US). **NISHIMOTO, Yutaka**; c/
o Takeda Pharmaceutical Company Limited, 26-1, Murao-
ka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012
(JP).

(74) Agent: MENDEZ, Julio J. et al.; Proskauer Rose LLP, One
International Place, Boston, MA 02110 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

(54) Title: COMPOSITIONS AND METHODS OF CRYOPRESERVING CELLS

Different cryo-formulations to cryopreserve wild-type iCART cells

Cryo-formulation Number (#)	Number of Mice (n)	Activation/Transduction Day	Treatment Groups
	5		Nalm6 cells in PBS (Control)
	5		Primary CART cells
	4	4/7	Fresh CART cells
1	3	4/8	CS10
2	1	4/8	Stem Cellbanker
3	2	4/8	BamBanker hRM
4	1	4/8	50% CS10 + 50% EM* (IMDM + 15% Human serum, w/ Cytokines#)
5	1	4/8	50% CS10 + 50% EM* (IMDM + 15% Human serum)
6	2	4/8	50% CS10 + 50% EM* (IMDM + 5% Human serum albumin)
7	1	4/8	80% Human Serum + 10% DMSO + 10% EM* (IMDM + 15% Human serum, w/ Cytokines#)
8	1	4/8	80% Human Serum + 10% DMSO + 10% EM* (IMDM + 15% Human serum)
9	2	4/10	50% CS10 + 50% EM* (IMDM + 15% Human serum, w/ Cytokines#)
10	2	4/8	50% CS10 + 50% Human Serum w/ Cytokines
11	2	4/8 (different source)	50% CS10 + 50% EM* (IMDM + 5% Human serum albumin)

FIG. 1

(57) Abstract: The present disclosure provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: dimethyl sulfoxide (DMSO), disaccharide, human serum, and IL-7 and/or IL-15. The present disclosure also provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: between about 1 w/v % and 10 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and between about 10 w/v % and 90 w/v % human serum. The present disclosure also provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: between about 1 w/v % and 10 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and between about 0.5 w/v % and 30 w/v % human serum albumin.

[Continued on next page]

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))